SLC1A5

Across TCGA pan-cancer cohorts, SLC1A5 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SLC1A5’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC1A5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC1A5 is over-expressed in tumor.

THCA, COAD, and HNSC are the cancer types where SLC1A5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC1A5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	+2.242	<.001	11	view →
COAD	Male	IV	+1.663	<.001	11	view →
HNSC	Male	All	+1.286	<.001	11	view →
STAD	Male	II,III,IV	+1.954	<.001	10	view →
LUSC	All	III,IV	+1.618	<.001	9	view →
LUAD	Female	III,IV	+0.983	<.001	9	view →
KIRC	Male	III,IV	+0.751	<.001	8	view →
CHOL	Male	All	+4.013	<.001	5	view →
PAAD	All	All	+1.557	.024	4	view →
LIHC	All	II,III,IV	+1.192	.001	4	view →
READ	All	All	+1.299	.005	2	view →
ESCA	All	All	+1.240	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SLC1A5–THCA

Open the THCA breakdown →